0950.HK
Unloved QualityAI neutralLee's Pharmaceutical Holdings Limited · Healthcare · Hong Kong · $80M cap · $38K/day traded
HKD 1.07 +0.9% · close 9 Nov · scored 10 Nov
Unloved Quality: Strong and cheap, but the market has not warmed to it.
As of 10 Nov 2026, the MoatMap Score for Lee's Pharmaceutical Holdings Limited (0950.HK) is 92/100, ranked against 25,000+ stocks in 38 markets (Quality 54, Value 95, Momentum 48, each scored against its sector).
Does the score work? Each tenth of the ranking, tracked monthly. See the record →
Lee's Pharmaceutical is a small Hong Kong-listed drug company focused on licensed and in-house products in China, trading at a low valuation with small insider purchases. There is little recent information on its pipeline or earnings trend, and Chinese drug price controls limit pricing power.
ABOUT LEE'S PHARMACEUTICAL HOLDINGS LIMITED
Read
Lee's Pharmaceutical Holdings Limited researches, develops, manufactures, and commercializes proprietary and licensed pharmaceutical products, focusing on cardiovascular, oncology, and gynecology. Its competitive advantage lies in focusing on niche therapeutic areas and a diversified pipeline of innovative drugs, leveraging both in-house R&D and strategic licensing. It is a specialty pharmaceutical company with a focus on specific therapeutic areas in China.
FINANCIAL SUMMARY (HKD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|---|
| Revenue | 1.3B | 1.2B | 1.1B | 1.4B | 1.4B | 3.2% | 1.5B |
| EPS (HKD) | 3.38 | 0.09 | 0.03 | 0.16 | 0.16 | -53.6% | 0.20 |
| Shares | 588.8M | 588.8M | 588.8M | 588.8M | 588.8M | 0.0% | 588.8M |
| Debt | 267.1M | 163.5M | 204.1M | 227.3M | 310.3M | 3.8% | 249.9M |
| Equity | 2.5B | 1.9B | 2.0B | 1.7B | 2.0B | -4.5% | — |
| Op CF | 210.7M | 283.6M | 110.1M | 242.0M | 332.9M | 12.1% | 383.2M |
| Inv CF | -370.3M | -256.1M | -145.2M | -190.2M | -235.8M | — | — |
| Fin CF | 61.0M | -128.6M | 13.4M | -2.0M | 35.6M | — | — |
No new 52-week low for 22 weeks, 11% above that low, but not back above a rising 50-day average.
Swung more than 57% of stocks we rank over the past year (volatility 46% a year).
How this is worked out
The MoatMap Score weighs the business, its price and its trend. The price check reads only the chart: the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 0950.HK are excluded.
| Ticker | Company | Mkt Cap | Score |
|---|---|---|---|
| 0950.HK | Lee's Pharmaceutical Holdings Limited(you) | $80M | 92 |
| 0239.HK | Pak Fah Yeow International Limited | $98M | 100 |
| 2348.HK | Dawnrays Pharmaceutical (Holdings) Limited | $183M | 99 |
| 2161.HK | JBM (Healthcare) Limited | $160M | 83 |
| 2633.HK | Jacobson Pharma Corporation Limited | $240M | 90 |
| 8049.HK | Jilin Province Huinan Changlong Bio-pharmacy Company Limited | $189M | 100 |
| 3839.HK | CPBIO Holding Company Limited | $239M | 87 |
| 0897.HK | Wai Yuen Tong Medicine Holdings Limited | $51M | 64 |
| 3613.HK | Beijing Tong Ren Tang Chinese Medicine Company Limited | $595M | 91 |
| 2005.HK | SSY Group Limited | $942M | 83 |
Peer medians: ROE 6.4% · P/E 10.7x · Gross margin 43.0%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.